Workshop on Leukocyte Reduction of Blood and Blood Components: An Update Alan E. Williams, Ph.D. Division of Blood Applications OBRR/CBER/FDA July 20,

Slides:

Advertisements

Similar presentations

Random Donor Pooled Platelets, Prophylaxis. Ofira Ben-Tal, MD. Director, Transfusion Medicine Tel-Aviv, Sourasky, Medical Center.

Advertisements

Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs, OBRR,

Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.

The Safety of the Blood Supply

FDA Panel Comments Adele Schneider, MD, FACMG Victor Center for the Prevention of Jewish Genetic Diseases, Director, Clinical Genetics Albert Einstein.

An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Current standards, donor safety, and blood supply

1 Babesia BPAC: FDA Perspective Sanjai Kumar, PhD Division of Emerging and Transfusion- Transmitted Diseases Office of Blood Research and Review CBER,

CBER Irradiated Blood Components Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.

Blood bank visibility & functionality in the EMR Meghan Delaney, DO, MPH Medical Director, Blood Bank, Seattle Children’s Hospital Assistant Professor,

Good Manufacturing Practices for Blood Establishments

Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.

CBER Blood Establishment Registration and Product Listing Jan O’Brien Blood Registration Coordinator DBA, OBRR, CBER September 15, 2009.

Welcome to the University of Minnesota Department of Medicine Education’s Global Health Course 2010.

Draft Guidance: Collection of Platelets by Automated Methods Comments to the Docket and Questions for the Committee Alan E. Williams, Ph.D. Director,

Click to edit Master title style Click to edit Master subtitle style February Regulatory framework for blood and blood components Transfusion Medicine.

TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

Workshop for Setting Regional and National Road Traffic Causality Reduction Targets in the ESCWA Region 16-17June, 2009 Abu Dhabi, United Arab Emirates.

G. Scott Gazelle, MD, MPH, PhD Director, Partners Radiology Partners Radiology Research Retreat February 26, 2010.

Monitoring Blood Supply Shortages The TRANS-Net Pilot Alan E. Williams, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 13, 2003.

Current Considerations on Plasma for Further Manufacturing Obtained from Whole Blood Donors Alan E. Williams, Ph.D. Associate Director for Regulatory Affairs,

Apheresis Blood Components

FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.

Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.

CBER Alternative Procedures “Variances” Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 15, 2009.

April The American Red Cross experience with TRALI Richard J Benjamin MD PhD Chief Medical Officer American Red Cross, Biomedical Headquarters Washington.

Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.

Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.

Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.

FDA Update: Particulate Matter Task Force Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting June 19, 2003.

Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.

C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.

Issues Related to Implementation of Blood Donor Screening for Infection with Trypanosoma cruzi Presentation to BPAC April 26, 2007 Robert Duncan, PhD.

Modeling Risk of vCJD in US Donors – Residual Risk and Efficiency of Donor Deferral Alan E. Williams, Ph.D. Director, Division of Blood Applications Office.

Evaluation of Proposed FDA Criteria for Evaluation of Radiolabeled Red Cell Recovery Trials Larry J. Dumont, MBA, PhD James P. AuBuchon, MD for the Biomedical.

Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.

CBER Common Problems on Source Plasma Inspections Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.

FDA Perspective on the PASSPORT Study FDA Perspective on the PASSPORT Study Salim A. Haddad, M.D. Laboratory of Cellular Hematology Division of Hematology.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Licensure of Apheresis Blood Products August 15, 2007 Lister Hill Auditorium, NIH Bethesda, MD.

Identification and Deferral of Tissue Donors for Possible BSE/vCJ-D Exposure: Estimating the Impact Alan E. Williams, Ph.D. Director, Division of Blood.

Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,

Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.

Slide 1 "CJD Lookback Study" (Research Study to Assess the Risk of Blood Borne Transmission of CJD) American Red Cross Blood Services TSEAC October 14,

Cancer Disparities Subcommittee Dr. Claudia Baquet – Chair University of Maryland.

United States Department of Agriculture Food Safety and Inspection Service Background and Overview of the FSIS Plan to Address Today’s Issues Daniel Engeljohn,

Transfusion Related Acute Lung Injury (TRALI)

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

An Interview with Two Senior Staff By TJ Bigelow.

David M. Deci, M.D. Director Office of Medical Student Education Associate Professor, Department of Family Medicine University of Wisconsin School of Medicine.

K-HEN Coaching Call 9/4/2012 Update on Adverse Drug Events Donna R. Meador K-HEN Project Director Dolores Hagan K-HEN Education and Data Manager.

CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.

Ann Intern Med. 2012;157(1): doi: / Figure Legend:

CDC’s 6|18 Initiative: Accelerating Evidence into Action American College of Preventive Medicine Utilizing the 6|18 Initiative to Address High Blood.

Irradiation WG Updates

Deputy Director, Division of Biostatistics No Conflict of Interest

PMC Policy Committee Meeting April 24, 2018

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Consideration of reducing the shelf life of SAGM RBCs

Impact of Emergency Department Visits and Hospitalization on Mobility Among Community-Dwelling Older Adults Cynthia J. Brown, MD, MSPH, Richard E. Kennedy,

Patient Involvement in the Development and Safe Use of

Maame Yaa “Maya” A. B. Yiadom, MD, MPH, MSCI

EXTENT OF CHANGES IN PRE AND POSTDONATION DONOR VARIABLES IN SINGLE AND DOUBLE DOSE PLATELETPHERESIS AND ITS IMPLICATIONS ON DONOR SAFETY Dr. R. Sreedevi.

The New Israeli Government: Views from Jerusalem and Washington

Presentation transcript:

Workshop on Leukocyte Reduction of Blood and Blood Components: An Update Alan E. Williams, Ph.D. Division of Blood Applications OBRR/CBER/FDA July 20, 2005

Workshop Goals: Review new evidence regarding leukocyte reduction for non-targeted recipient populations. (Assume accepted medical value of leukocyte reduction for targeted recipient populations) Update on leukoreduction failures and adverse events –Incomplete filtration –Incomplete WBC removal –Recipient adverse events –Blood establishment experiences Practical, effective process control

Morning Agenda: Welcome and Introduction Jay S. Epstein, M.D. Director, Office of Blood Research and Review, (OBRR), CBER, FDA U.S. Regulatory Considerations and International Policies Regarding Leukocyte Reduction Alan E. Williams, Ph.D. Director, Division of Blood Applications, OBRR, CBER, FDA

Morning Agenda (cont.): Recent Studies Addressing the Value of Pre- storage Leukoreduction for Non-Targeted Recipients Robertson Davenport, MD, University of Michigan The Yale-New Haven Hospital Universal Leukocyte Reduction Program Edward Snyder, M.D. Yale University School of Medicine

Morning Agenda (cont.): The Impact of Pre-storage Leukoreduction Among Transfused Trauma Patients Avery Nathans, MD, PhD, MPH, Univ of Washington Adverse Events and Manufacturing Failures Associated with Leukoreduction. David Stroncek, MD, Department of Transfusion Medicine, NIH Questions for morning speakers and Open Public Hearing

Afternoon Agenda: Practical Aspects of Pre-storage Leukoreduction in a Blood Establishment, including Use of Pooled Samples for Enumeration of Residual Leukocytes Timothy Malone, Florida Blood Services Practical Aspects of Pre-storage Leukoreduction in Blood Establishments Dan Waxman, M.D., America’s Blood Centers Fred Walker, Ph.D. American National Red Cross

Afternoon Agenda (cont.): FDA Current Considerations: Pre-Storage Leukoreduction: Process Validation, Quality Assurance and Monitoring, Processing, Testing, and Licensure Alan Williams, PhD and Sharyn Orton, PhD, Division of Blood Application, OBRR, CBER Questions for Afternoon Speakers and Open Public Hearing

Afternoon Agenda (cont.): Panel Discussion: Dana Devine, Ph.D. Larry Dumont,Ph.D. Celso Bianco, MD Michael Busch, MD Ph.D. Harvey Klein MD Gary Moroff, Ph.D. Moderator: Alan E. Williams, Ph.D.

Afternoon Agenda (cont.): Prion Reduction by Filtration Luisa Gregori, Ph.D. University of Maryland Pall Leukotrap Affinity Filtration System:Update Jerry Ortolano, PhD, Pall Corporation